Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 23Recurrence 6Neoplasms 4Neoplasms, Plasma Cell 3Lymphoma, Non-Hodgkin 3Leukemia, Myeloid, Acute 3Immunoglobulin Light-chain Amyloidosis 3Hematologic Neoplasms 3Paraproteinemias 2Hematologic Diseases 2Corneal Diseases 2Carcinoma, Non-Small-Cell Lung 2Blood Protein Disorders 2Various Advanced Cancer 1Triple Negative Breast Neoplasms 1Proteostasis Deficiencies 1Pancreatic Neoplasms 1Neoplasm, Residual 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Hodgkin Disease 1Glioblastoma 1Amyloidosis 1

Interventions

romidepsin 7N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Vincristine 4Gemcitabine 4Doxorubicin 4Cyclophosphamide 4Prednisone 3Lenalidomide 3Azacitidine 310-propargyl-10-deazaaminopterin 3pembrolizumab 2ixazomib 2fludarabine phosphate 2copanlisib 2Whole-Body Irradiation 2Vitamin B 12 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Mycophenolic Acid 2Folic Acid 2Etoposide 2Dexamethasone 2Cyclosporine 2Bortezomib 2venetoclax 1tislelizumab 1tazemetostat 1relatlimab 1prednisolone phosphate 1pomalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, T-Cell, Peripheral × daratumumab × Clear all
NCT04068597 2025-12-18

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

CellCentric Ltd.

Phase 1/2 Recruiting
250 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡